Vanda Pharmaceuticals Inc (Nasdaq:VNDA), a US-based global biopharmaceutical company, announced on Tuesday that it has received approval from the US Food and Drug Administration (FDA) for NEREUS (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting induced by motion.
This approval marks the first new pharmacologic treatment in motion sickness in over four decades, the company said.
The product's efficacy is supported by positive data from three pivotal clinical trials -- two Phase 3 real-world provocation studies carried out on boats (Motion Syros and Motion Serifos) and one additional supporting study -- with participants who had documented histories of motion sickness.
Vanda is planning to launch NEREUS in the coming months.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA